				OIPE MASS			AF/16
AMENDMENT	ΓTRANSMI	ITTAL I	LETTER	NON 0 8 JOHN PA	ATTORNEY'S DOCKET NO.: 0147-1 DIV1		
SERIAL NUMBER: FILING DATE:				EXAMPLER:		GROUP ART	UNIT:
10/730,831 December 9, 20			per 9, 200	EXAMPLE 13	er J. Nichols	ichols 1647	
GROWTH FA	ACTOR AN EART DIS	ID REL EASE	BLAST (	GROWTH FACTO ROTEINS IN THE	R, VASCULAI	R ENDOT OF ACU	HELIAL TE AND
INVENTOR(s): Wa			R FOR PAT	TENTS:	<del></del>		
Transmitted herev	vith is an ame	ndment in		identified application. T	he fee has been calc	ulated as she	own below.
	Τ		I - ''' - 'I	AIMS AS AMENDED	1	T	
(1)	CLAIMS REM AFTER AMEN		(3)	(4) HIGHEST NUMBER PREVIOUSLY PAID FOR	(5) NO. OF EXTRA CLAIMS PRESENT	(6) RATE	(7) ADDITIONAL FEE
TOTAL CLAIMS	8		MINUS	20	0	X \$25	\$ 0.00
INDEP. CLAIMS	2		MINUS	3	0	X \$100	\$ 0.00
					L ADDITIONAL FEE THIS AMENDMENT		\$ 0.00
No addition  Charge \$ copy of the under A Check A triplication	his sheet is enersigned petition for \$	closed.  ons for a constant is enclosed.	to Depone month to sed to coverenclosed.	S SPACE is less than 3, write the fee for this time extension for filing to the fee for this time extension.	this document under	37 C.F.R. 1	A triplicate
	· P	HOHE			reg. Nulliver		
				osited with the United S.O. Box 1450, Alexandri		on Noven	



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wayne P. Franco

Group Art Unit:

1647

Serial No.:

10/730,831

Examiner:

Daniel C. Gamett

Filed:

December 9, 2003

For:

METHODS OF USE OF FIBROBLAST GROWTH FACTOR,

VASCULAR ENDOTHELIAL GROWTH FACTOR AND

RELATED PROTEINS IN THE TREATMENT OF ACUTE

AND CHRONIC HEART DISEASE

Docket No.:

0147-1 DIV1

Ernest D. Buff & Associates, LLC

231 Somerville Road Bedminster, N.J. 07921 November 7, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## **AMENDMENT UNDER 37 CFR 1.116**

In response to the Office Action dated September 13, 2005, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.